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Most studies concerning a possible protective role of carot-
enoids against cancer focus on serum carotenoid levels. We
have used Raman microspectroscopy to study the intracellu-
lar amounts of carotenoids in lymphocytes of lung cancer
patients and of healthy individuals. Our results indicate a
significant decrease of carotenoids in lung carcinoma patients
compared with healthy individuals, particularly in adenocarci-
noma patients. Carotenoid supplementation raised the se-
rum concentration in 2 lung cancer patients up to normal
levels, whereas intracellular content remained significantly
lower. This indicates that carotenoid uptake by lymphocytes
is not only dependent on serum carotenoid concentration.
Our findings indicate that Raman microspectroscopy, a re-
cently developed technique to measure intracellular levels of
drugs, is also well suited to obtain quantitative data on
carotenoid amounts inside cells. Int. J. Cancer 74:20–25.
r 1997 Wiley-Liss, Inc.
Numerous studies indicate that low serum carotenoid concentra-
tion and a low dietary intake of carotenoids are related to an
increased risk of cancer, especially lung and stomach cancer (Peto
et al., 1981; Ziegler, 1989; Bendich, 1990; van Poppel, 1993;
Krinsky, 1993). Three different mechanisms have been suggested
to explain the protective effect of carotenoids: provitamin A
activity (Lotan, 1980; Lupulescu, 1993), singlet oxygen and radical
quenching (Burton and Ingold, 1984; Krinsky, 1989) and modula-
tion of the immune system (Alexander et al., 1985; Jyonouchi et
al., 1991).
Some of the problems that arise when assessing the relationships
between cancer risk in humans and serum carotenoid concentra-
tions are related to the large fluctuations of the latter, which depend
on intake, and also the fact that dietary intake does not reflect the
actual uptake in serum. Observations that carotenoids can modulate
the immune system prompted us to investigate whether differences
might exist between the carotenoid contents of lymphocytes of
healthy individuals and of cancer patients and how this relates to
the concentration of carotenoid in serum.
We have shown that Raman microspectroscopy is a sensitive
technique for analysis of the carotenoid content of human lympho-
cytes (Puppels et al., 1993). We found that the highest carotenoid
concentration for healthy donors was observed in the Gall body, a
cytoplasmic (lipid) spherule, present in some CD41 and CD81
cells (Gall, 1936; Bessis, 1973). The carotenoid concentration
inside the Gall body was found to be about 1,000 times higher than
the serum concentration. Such high carotenoid concentration in the
Gall bodies of healthy donors indicates that Gall bodies are storage
sites for carotenoids. In the present study we used Raman
microspectroscopy to investigate whether differences exist in Gall
body carotenoid concentration in lymphocytes of lung cancer
patients and healthy donors. The effect of dietary b-carotene
supplementation on serum and intracellular carotenoids was inves-
tigated in a healthy individual and in 2 lung cancer patients.
MATERIAL AND METHODS
Raman microspectroscopy
Raman microspectroscopy is a spectroscopic technique that can
be used to obtain information about the molecular composition of a
sample with a spatial resolution equal to that of a normal optical
microscope. Raman scattering is a process in which there is energy
transfer between the incident light and the scattering molecules. In
most cases, the photons transfer some energy to the scattering
molecule, which brings the molecule to one of the higher vibra-
tional energy levels. The energy loss of the scattered photons
results in a wavelength shift that is characteristic for that vibration
of the molecule. The Raman spectrum therefore gives a fingerprint
of (all excitable vibrational levels of) the molecules in the
measuring volume. The intensity of a Raman line is linearly
dependent on the concentration of molecules (with that particular
vibration) in the sample. The wavelength shifts of a Raman line,
relative to the laser line, are expressed in cm21: Dcm21 5
[1/lin 2 1/lout] 3 107 (with l in nm). Carotenoids are strong
Raman scatterers, especially the single and double conjugated
carbon bond-stretches, which give rise to large Raman peaks at
about 1,150 and 1,525 cm21, respectively. All carotenoids present
in humans give similar spectra, with small changes due to
differences in structure. The peak at about 1,150 cm21 is present for
all carotenoids.
For determination of the carotenoid content of Gall bodies, we
used a normal (non-confocal) Raman microscope with 63 3 water
immersion objective. Figure 1a shows a schematic drawing of the
set-up used in our study. Red light (647 nm) was used to minimize
bleaching of the carotenoids. All measurements were carried out
using the same conditions: 4 mW laser light on the sample and 15
sec photon collection time on the camera. Figure 1b shows a
photograph of a lymphocyte containing a Gall body. In Figure 1c a
typical spectrum obtained from a Gall body of a healthy individual
is shown.
Calibration of the peak height vs. the concentration was done
using solutions of b-carotene in tetrahydrofuran (THF) with
different molarities (data not shown). From the background sub-
tracted peak heights at 1,150 cm21, it was calculated that the peak
intensity is about 1,600 counts/mM b-carotene for the conditions
used in our study, the detection limit being about 5 mM.
Preparation of samples
Peripheral blood of healthy volunteers and of lung cancer
patients was collected in the morning by venipuncture in the arm,
using a siliconized Vacutainer to collect serum and a heparinized
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Vacutainer to collect white blood cells. Serum was isolated after
centrifugation, and lymphocytes were isolated using the Ficoll-
Paque method (Bo¨yum, 1968). Serum was collected simulta-
neously and stored in the dark at 280°C until analysis using
high-performance liquid chromatography (HPLC). Part of the
isolated lymphocytes was immuno-stained with CD4-PE and
CD8-FITC (Becton Dickinson, San Jose, CA) and analyzed with a
fluorescence microscope.
Fluorescence microscopy
A fluorescence microscope (Nikon, type Optiphot EF) with blue
light excitation was used to study the immuno-labeled lympho-
cytes; 100 cells of each sample were counted to determine the
relative amounts of CD41 and CD81 lymphocytes. In addition, the
number of Gall bodies was counted and their diameter was
measured in all cells, using a calibrated eyepiece micrometer.
HPLC
Serum samples were analyzed for the presence of carotenoids,
using HPLC, at the T.N.O. Research Laboratory, Zeist, The
Netherlands, as described previously (van Vliet et al., 1991).
Amounts of the 5 major carotenoids present in humans (b-carotene,
a-carotene, lycopene, b-cryptoxanthine and lutein/zeaxanthin)
were determined.
b-carotene supplementation
Dietary supplementation was given in the form of capsules with
25 mg crystalline b-carotene, generously provided by Merck
(Darmstadt, Germany). Because the actual uptake of crystalline
b-carotene is low, a high dose of 100 mg/day (intake at one meal)
was chosen to obtain clear responses compared with the normal
dietary intake of b-carotene. Cells and serum of all individuals
were measured prior to the study to establish baseline levels. Blood
samples were drawn on days 1, 2, 3, 5, 8, 13 and 17 after the first
supplementation.
Statistical analysis
The significance of differences between the groups of healthy
donors and lung cancer patients was calculated for all measured
parameters using an unpaired double-tailed t-test.
RESULTS
The first part of this pilot study focused on possible differences
in the carotenoid content of Gall bodies comparing healthy persons
with lung cancer patients. From 23 healthy donors, and 19 donors
with different types of lung cancer, peripheral blood was collected
as described above; lymphocytes were isolated and measured
within 24 hr. The results are summarized in Table I. The differences
between the 2 groups are clear and significant. The 2 groups were
not age matched: if the age-matched part of the group of healthy
donors (n 5 11) is compared with the lung cancer group, only the
difference in average Raman intensities remains ( p , 0.05). These
findings suggest that carotenoid concentrations decrease with age.
The individual values of the total serum carotenoid concentra-
tions, measured with HPLC, are shown in Figure 2a. This clearly
shows that the differences between the ‘‘all healthy’’ and ‘‘lung
cancer’’ groups are significant, whereas the difference between the
age-matched groups ‘‘healthy old’’ and ‘‘lung cancer’’ is not. The
individual values of the average Gall body carotenoid concentra-
tions, measured with Raman microspectroscopy, are shown in
Figure 2b. Here also, the differences between ‘‘healthy old’’ and
‘‘lung cancer’’ are significant.
There is a positive correlation between the individual serum
carotenoid and Gall body concentrations, although the correlation
coefficients are low (total 0.47; healthy 0.36; lung cancer 0.25).
The second part of our study focused on the influence of
short-term high-dose b-carotene supplementation on the carot-
enoid amounts present in Gall bodies in lymphocytes of healthy
individuals and lung cancer patients. This was performed on 3
individuals, one healthy person and 2 advanced lung cancer
patients (lung adenocarcinoma and squamous cell lung cancer).
Figure 3a shows the serum carotenoid concentration response
following supplementation with 100 mg b-carotene/day, as a
function of time. The results clearly show that all serum carotenoid
concentration values rise immediately after supplementation and
continue thereafter. These values in the lung cancer patients were
lower at the start than those in the healthy volunteer but increased
to the same values as those in the healthy volunteer after 8 days of
supplementation, the relative increase in the lung cancer patients
thus being 2 to 3 times more marked than in the healthy individual.
The effects of supplementation on carotenoid content in the Gall
bodies is shown as a function of time in Figure 3. This figure shows
that the response is comparable in all cases. All baseline levels
increase by about 50%. Such an increase was observed during the
first 5 days of supplementation, while the carotenoid concentration
remained constant thereafter. The amount of carotenoids in Gall
bodies in both lung cancer patients did not reach the values of the
healthy individual. This is in contrast with the findings in serum.
This suggests that carotenoids are not taken up by simple diffusion.
DISCUSSION
The following findings emerge from this pilot study:
a. Raman microspectroscopy is well suited for determining
carotenoid concentrations inside cells.
b. Intracellular carotenoid amounts in lymphocytes decrease
with age; in age-matched groups, the carotenoid content of
lymphocytes is significantly lower in the lung cancer patients.
c. A very weak correlation only exists between the carotenoid
content in lymphocytes and the serum carotenoid concentration.
d. Carotenoid supplementation restores normal carotenoid con-
centration in the serum, but intracellular values remain significantly
low (i.e., 50% increase in lymphocyte carotenoid levels and 3- to
5-fold increase in serum concentration).
The intracellular carotenoid concentration may thus be a more
accurate parameter than that in the serum.
TABLE I – MAIN DIFFERENCES BETWEEN HEALTHY PERSONSAND LUNG
CANCER PATIENTS FOR THE PARAMETERS MEASURED
Healthy
(n 5 23)
x 6 SD
Lung cancer
(n 5 19)
x 6 SD
p1
% cells with GBs 22.0 6 12.6 16.0 6 6.2 ,0.05
Average number of
GBs/cell
1.11 6 0.15 1.00 6 0.21 ,0.05
Average GB Raman
intensity
101.7 6 62.9 50.3 6 31.3 ,0.005
Total GB carotenoid
content2
2.88 6 3.5 0.63 6 0.7 ,0.05
Serum lutein 0.33 6 0.14 0.25 6 0.12 ,0.05
Serum b-cryptoxan-
thine
0.28 6 0.24 0.24 6 0.20 NS
Serum lycopene 0.42 6 0.41 0.13 6 0.10 ,0.01
Serum a-carotene 0.06 6 0.05 0.03 6 0.02 ,0.05
Serum b-carotene 0.36 6 0.30 0.21 6 0.12 NS
Total serum carot-
enoids
1.45 6 0.81 0.86 6 0.40 ,0.01
1p values denote the chance that values from both groups have the
same origin (calculated with unpaired two tailed t-test); differences are
considered significant if p , 0.05. Raman intensity in counts/(15 sec).
GB, Gall body; x, mean; SD, standard deviation; NS, not signifi-
cant.–2In arbitrary units.
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FIGURE 1
The results of short-term b-carotene supplementation show that
there is no simple relation between serum and intracellularlympho-
cyte carotenoid content. During b-carotene supplementation the
serum carotenoid concentration rises continuously, while there is
only a small increase in the Gall body carotenoid content during the
first days. Our observation that Gall body carotenoid concentration
rises during the first days only is not related to saturation of the Gall
bodies with carotenoids, since the variation in individual Gall body
concentrations was not significantly decreased (data not shown). In
addition, even higher carotenoid contents have been observed in
other healthy individuals.
FIG. 1 – (a) Schematic representation of the Raman microspectro-
scope used in our study. The laser is focused to a spot (0.5 µm in
diameter) in the cell, using a normal CCD camera and TV for
determining the exact place.After rejection of the laser line with a filter,
the Raman scattered light is coupled into a spectrometer, and the
spectrum of the dispersed light is projected on a liquid N2-cooled
camera. The spectra are stored using a normal personal computer. (b)
Photograph of a lymphocyte containing a Gall body (arrow). Scale
bar 5 2 µm. (c) Typical spectrum from a Gall body of a healthy indi-
vidual. The peak height at 1,150 cm21 (background subtracted) is propor-
tional to the carotenoid concentration inside the Gall body (see text).
FIG. 2 – (a) Concentration of total serum carotenoids (µmoles/l), measured with HPLC. Bars, average 6 standard deviation. Difference between
‘‘all healthy’’ group and ‘‘lung cancer’’ group is significant ( p 5 0.006). Difference between ‘‘healthy, old’’ group and ‘‘lung cancer’’ group is not
significant (p 5 0.72). (b) Concentration of total carotenoids in the Gall body of lymphocytes, measured as Raman intensity [counts/(15 sec);
every point is an average of 25 measurements in different cells]. Bars, average 6 standard deviation. Difference between ‘‘all healthy’’ group and
‘‘lung cancer’’ group is significant ( p 5 0.003). Difference between ‘‘healthy, old’’ group and ‘‘lung cancer’’ group is significant ( p 5 0.04).
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Our findings are based on a relatively small number of explor-
atory experiments. They suggest that evaluation of intracellular
carotenoid concentration may provide additional and different
information, compared with measurements in the serum. Our
results therefore stress the need to investigate the significance of
the high carotenoid amounts found in lymphocytes, and they
open novel ways to study the mechanism(s) that may quantitatively
correlate carotenoids and lung cancer.
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